OpenAI said Tuesday it acquired Orchestra Bio, whose AI agents track drug studies, as it seeks to connect its Rosalind research tools with the work required to develop potential medicines.
OpenAI plans to bring Orchestra Bio’s staff and technology into Rosalind, its collection of life sciences research models and tools. The company did not disclose the purchase price or set a release date for the planned tools.
Drug programs involve internal teams and outside partners that often use separate systems, OpenAI said. It aims to use agents to help those teams follow studies and coordinate the work involved in advancing potential medicines.
Orchestra Bio’s software shows how a change in one part of a program may affect other work. Its agents assemble information and possible responses for scientists and program leaders, who remain responsible for decisions.
GPT-Rosalind, introduced April 16, is OpenAI’s model for research in drug discovery, biology and chemistry. Rosalind Workbench provides tools for analyzing results and planning experiments. Orchestra Bio’s software is designed to help coordinate work across drug-development programs.
